AAV vs. Non-Viral Gene Delivery: Which Is Better for In Vivo Gene Therapy?

This distinction has important consequences:

• Viral vectors inherently possess high transduction efficiency, reflecting their biological origins

• Non-viral systems offer greater design flexibility, but often require optimization to overcome delivery barriers

In most cases, non-viral approaches result in transient expression, particularly when delivering RNA payloads or gene-editing components.

From a manufacturing perspective, AAV and non-viral systems represent two fundamentally different paradigms.

AAV production relies on complex, cell-based systems, typically involving transient transfection of mammalian or insect cells, followed by multi-step purification processes. These workflows introduce variability and scalability challenges, particularly when separating full and empty capsids.

As a result, AAV manufacturing remains:

• resource-intensive

• difficult to scale

• associated with high cost of goods

Non-viral systems (particularly LNPs) are produced using chemical or microfluidic processes, enabling greater consistency and scalability.

Advantages include:

• rapid production timelines

• platform-based manufacturing

• easier tech transfer across programs

This difference has significant implications for commercialization, especially as gene therapies move toward larger patient populations and chronic indications.

AAV vectors benefit from a relatively mature regulatory foundation, with multiple approved therapies demonstrating long-term efficacy across indications, such as retinal disease and spinal muscular atrophy.

However, key limitations remain:

• immune responses to viral capsids

• inability to redose due to neutralizing antibodies

• dose-related safety concerns

Non-viral systems, while newer in gene therapy, are supported by regulatory experience from RNA therapeutics and vaccines. These platforms are increasingly attractive for:

• repeat-dose regimens

• transient or controllable expression

• gene editing applications

Importantly, regulators are becoming more comfortable with non-viral delivery as clinical data accumulates, particularly in RNA-based therapies.

AAV is generally preferred when:

• Long-term or potentially curative expression is required

• The therapeutic gene fits within size constraints (~5 kb)

• A single-dose treatment is desired

• Established tissue tropism (e.g., liver, CNS, retina) can be leveraged

Non-viral delivery is often preferred when:

• Large or complex payloads are required (e.g., CRISPR systems)

• Repeat dosing is necessary

• Transient expression is sufficient or advantageous

• Manufacturing scalability and cost are critical

• Platform flexibility is needed across multiple programs

Notably, non-viral systems are increasingly enabling applications that are not feasible with AAV, particularly in gene editing.

There is no universally superior platform: only platforms that are better aligned with specific therapeutic goals.

Choose AAV when durability and one-time treatment are the primary objectives, and payload size is not limiting.

Choose non-viral delivery when flexibility, repeat dosing, or large genetic payloads are required.

In practice, the field is moving toward a complementary model, where AAV and non-viral systems coexist as distinct but synergistic tools in the gene therapy toolbox.